Contineum Therapeutics, Inc. (NASDAQ:CTNM) Given Average Rating of “Moderate Buy” by Analysts

Contineum Therapeutics, Inc. (NASDAQ:CTNM) has been given an average rating of “Moderate Buy” by the seven analysts that are presently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating on the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $19.00.

Several research analysts recently commented on CTNM shares. Robert W. Baird cut their price objective on shares of Contineum Therapeutics from $16.00 to $14.00 and set an “outperform” rating for the company in a report on Monday, November 24th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Contineum Therapeutics in a report on Wednesday, January 21st. Royal Bank Of Canada decreased their price objective on Contineum Therapeutics from $25.00 to $22.00 and set an “outperform” rating on the stock in a research note on Friday, November 21st. Leerink Partners started coverage on Contineum Therapeutics in a report on Thursday, November 13th. They set an “outperform” rating and a $22.00 price objective on the stock. Finally, Wall Street Zen lowered Contineum Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, January 10th.

Institutional Trading of Contineum Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. purchased a new stake in Contineum Therapeutics in the 4th quarter worth approximately $43,000. Strs Ohio bought a new position in shares of Contineum Therapeutics in the first quarter worth $27,000. Bank of America Corp DE raised its position in shares of Contineum Therapeutics by 500.0% in the third quarter. Bank of America Corp DE now owns 7,236 shares of the company’s stock worth $85,000 after buying an additional 6,030 shares in the last quarter. Qube Research & Technologies Ltd bought a new stake in Contineum Therapeutics during the second quarter valued at $43,000. Finally, Marex Group plc purchased a new position in Contineum Therapeutics during the second quarter worth about $45,000.

Contineum Therapeutics Stock Up 3.6%

Shares of NASDAQ:CTNM opened at $15.00 on Friday. The firm has a market capitalization of $437.70 million, a PE ratio of -6.67 and a beta of 1.18. The company has a 50-day moving average price of $12.06 and a two-hundred day moving average price of $10.80. Contineum Therapeutics has a twelve month low of $3.35 and a twelve month high of $15.48.

About Contineum Therapeutics

Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist.